Cart
sales@molnova.com
Home - Products - Membrane Transporter/Ion Channel - Carbonic Anhydrase - Girentuximab

Girentuximab

Girentuximab

Catalog No. M36663

Girentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPUP).

Size Price / USD Stock Quantity
2MG 337 Get Quote
5MG 558 Get Quote
10MG 896 Get Quote
100MG 2277 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Girentuximab
  • Brief Description
  • Description
  • Storage
  • Note
    Research use only, not for human use.
  • Reference
    1. Chamie K, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3(7):913-920. ?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • (Iso)-Samixogrel

    (Iso)-Samixogrel shows activity against Carbonic anhydrase and Cyclooxygenase 2.

  • Disulfamide

    Disulfamide is an orally active carbonic anhydrase inhibitor with an IC50 value of 0.07 μM. Disulfamide has a diuretic effect by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal convoluted tubules.

  • Benzolamide

    Benzolamide inhibits carbonic anhydrase effectively and low-threshold calcium currents in hippocampal pyramidal neurons.

Sign In Join Free